Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor - Abstract

INTRODUCTION: Retroperitoneal lymph node dissection (RPLND) for the treatment of testicular germ cell tumor is technically difficult and associated with significant morbidity.

We postulated that a novel midline extraperitoneal (EP) approach might minimize the morbidity.

TECHNICAL CONSIDERATIONS: We describe a midline extraperitoneal approach in detail. The operative time, estimated blood loss, lymph node yield, return of bowel function, length of stay, and postoperative complications were retrospectively reviewed. From April 2010 to May 2011, 12 consecutive patients underwent EP-RPLND at 2 tertiary centers by a single surgeon, including 5 primary and 7 postchemotherapy RPLNDs. The clinical characteristics and outcomes were compared with those from a matched cohort of transperitoneal-RPLND patients.

RESULTS: The median follow-up was 173 and 201 days in the EP and transperitoneal groups, respectively. The EP group had a shorter mean operative time of 292 versus 337 minutes (P = .02) and lower estimated blood loss of 305 versus 575 mL (P = .05). More lymph nodes were retrieved in the EP group (44 vs 27 nodes, P = .0006). Finally, an earlier return of bowel function (1.7 vs 2.9 days, P = .0001) and a shorter median length of stay (3.3 vs 5.3 days, P = .0001) was seen in the EP group.

CONCLUSION: EP-RPLND can be performed safely without prolonged operative times or compromised lymph node retrieval, even in the postchemotherapy setting, and is associated with a faster return of bowel function and shortened length of stay.

Written by:
Kim P, Syan-Bhanvadia S, Djaladat H, Faber K, Tadros NN, Nichols C, Daneshmand S.   Are you the author?
University of Southern California Institute of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033-9178, USA.

Reference: Urology. 2012 Oct;80(4):941-5.
doi: 10.1016/j.urology.2012.07.006


PubMed Abstract
PMID: 22951007

UroToday.com Testicular Cancer Section

 

 

 

 

 

email news signup